BioNTech (NASDAQ: BNTX) agrees to buy FDA priority review voucher for $205 million

What happened

BioNTech SE (NASDAQ: BNTX) agreed to buy an FDA priority review voucher from Scholar Rock, Inc. (Nasdaq: SRRK) for $205 million in cash.

BioNTech announced the deal on Nov. 10. It plans to use the voucher to support a future filing for an asset in its late-stage oncology pipeline. Chief Financial Officer Ramon Zapata-Gomez and Chief Operating Officer Dr. Sierk Poetting signed the Form 6-K.

The deal has not closed. It needs customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

Key numbers

Metric	Latest	Change	Source
Total cash consideration for the voucher	$205 million		SEC 6-K, Exhibit 99.1
Priority review vouchers to be acquired	1		SEC 6-K
Applications covered by the voucher	1		SEC 6-K, Exhibit 99.1

Read more: BioNTech (BNTX) company research

What the voucher does

A priority review voucher, or PRV, gives one application priority review at the US Food and Drug Administration. BioNTech's statement says this cuts the target FDA review time and could lead to faster approval.

So BioNTech is paying cash for time on one filing. The money goes to Scholar Rock, the seller. It buys a regulatory right, not a drug candidate.

The company says its late-stage oncology pipeline includes immunomodulators, antibody drug conjugates and mRNA cancer immunotherapies. The voucher covers one application, so its benefit can be used only once.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

Why it matters

OptimistFi has argued that BioNTech works only if its mRNA and immunotherapy platform becomes a durable non-COVID oncology business before vaccine cash flows and R&D losses erode the option value.

Seen that way, the voucher is a bet on timing. It spends part of the company's cash to speed one oncology filing, which fits the reinvestment story.

The direction is mixed. A faster review helps only if an asset reaches an application. The voucher does not make approval more certain. It is also a one-time purchase of a single voucher.

What could limit the payoff

The main limit is what a voucher cannot do. It shortens the review of one application. Clinical and commercial success must still come from the asset itself.

BioNTech's statement lists several risks. They include uncertainty in research and development and in meeting expected clinical endpoints. They also include the timing and likelihood of regulatory approval for its product candidates.

The statement also lists the parties' ability to meet closing conditions as a risk to the deal.

What's next

The first test is Hart-Scott-Rodino clearance and closing. If the deal closes, BioNTech holds the voucher. If clearance stalls, the plan rests on a voucher it does not yet own.

The second test is the future filing of the late-stage oncology asset that will use the voucher. That filing would let investors compare the actual FDA review with the shortened target timeline the voucher is meant to provide.

More from OptimistFi

• BNTX stock: research and coverage of BioNTech
• Stock research on every company OptimistFi covers

From OptimistFi Perps